PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).
Xuewei Ding(Tianjin Medical University Cancer Institute and Hospital), Han Liang(The University of Texas MD Anderson Cancer Center), Jingyu Deng(Chinese Academy of Medical Sciences & Peking Union Medical College), Leping Li(Shandong University), Qun Zhao(Hebei Medical University), Liang Shang(Shandong University), Wenbai Huang(Tianjin Medical University Cancer Institute and Hospital), Rupeng Zhang(Second Affiliated Hospital of Xi'an Jiaotong University), Longgang Wang(Yanshan University), Bin Li(Shanghai Jiao Tong University), Yong Liu(Southwest Medical University), Xuejun Wang(Wuhan University), Ning Liu(Institute of Pomology), Mingzhi Cai(Tianjin Medical University Cancer Institute and Hospital), Jiancheng Zhang(Union Hospital), Liangliang Wu(Beijing Institute of Aeronautical Materials), Honghai Guo(Hebei Medical University), Baogui Wang(Tianjin Medical University Cancer Institute and Hospital), Bin Ke(Tianjin Medical University Cancer Institute and Hospital), Jie Chai(Shandong First Medical University)
Cited by 30
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656
A pan-cancer proteomic perspective on The Cancer Genome Atlas
|Nature Communications|2014|641